ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2025
Efficacy and safety of oral 5-FU-based adjuvant chemotherapy for geriatric patients with colorectal cancer: Integrated analysis of seven clinical trials conducted at the Japanese Foundation for Multidisciplinary Treatment of Cancer.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of oral 5-FU-based adjuvant chemotherapy for geriatric patients with colorectal cancer: Integrated analysis of seven clinical trials conducted at the Japanese Foundation for Multidisciplinary Treatment of Cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAdjuvant chemotherapy after radical resection is recommended for patients with high-risk Stages II and III colorectal cancer (CRC). However, the efficacy and safety of adjuvant chemotherapy in geriatric patients require elucidation.
methodsWe analysed data from seven clinical trials conducted by the Japanese Foundation for the Multidisciplinary Treatment of Cancer. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Survival analysis was performed using a Cox proportional hazards model.
resultsThis study included 7756 non-geriatric (<70 years) and 1706 geriatric patients (≥70 years). Adjuvant chemotherapy significantly improved the 5-year overall survival in non-geriatric patients (81.6% vs. 73.6%, p < 0.001) but did not significantly improve the survival rate in geriatric patients (78.9% vs. 76.1%, p = 0.129). However, adjuvant chemotherapy was effective for N+ geriatric patients (hazard ratio, 0.48; 95% confidence interval, 0.35-0.66; p < 0.001). Adverse events associated with adjuvant chemotherapy were significantly more frequent in geriatric than in non-geriatric patients.
conclusionAdjuvant chemotherapy in geriatric patients with node-positive CRC was as effective as in non-geriatric patients, although no benefit was shown in geriatric patients with node-negative CRC. More adverse events were observed in geriatric patients than in non-geriatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.